MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 05-16-2026
LogicBio Therapeutics DSO Ratio 2011-2026 | LOGC
Annual DSO Ratio LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.88 | 13.9 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.9 | 9.88 | 11.9 |
Quarterly DSO Ratio LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.01 | 0.86 | 0.97 | - | 4.22 | 9.44 | 34.8 | - | 25.9 | 24.9 | 11.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.8 | 0.86 | 12.7 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Happiness Biotech Group Limited
HAPP
|
29 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
559 | $ 1.66 | 1.22 % | $ 194 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
321 | $ 31.65 | 2.59 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 53.53 | 3.76 % | $ 4.81 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.76 | 4.15 % | $ 258 M |  Israel |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
39.1 | $ 32.4 | 3.55 % | $ 872 M | USA |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M |  Germany |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
2.16 K | - | - | $ 13.1 M | Canada |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Hutchison China MediTech Limited
HCM
|
93.9 | $ 11.72 | -0.26 % | $ 10.1 B | China |
 |
Heron Therapeutics
HRTX
|
198 | $ 0.91 | 3.0 % | $ 152 M | USA |
 |
ImmuCell Corporation
ICCC
|
47.5 | $ 10.63 | 1.24 % | $ 95.9 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | USA |
 |
Anika Therapeutics
ANIK
|
76.5 | $ 14.81 | -0.54 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 76.49 | 0.55 % | $ 12.2 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |